Michael Camp, MD
Interventional Cardiology · Mountain Home, ARNPI 1558363622
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 309 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in AR, where the typical reported total is $7,561.
Across 309 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$753
- Bard Peripheral Vascular, Inc.$674
- Novartis$565
- Shockwave Medical, Inc$562
- Abiomed$341
- plus $2K from 32 others
What the payments were for
- Travel & lodging$3816%
- Food & beverage$6,14993%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 51 | $1,531 |
| Boston Scientific | 33 | $753 |
| Bard Peripheral Vascular, Inc. | 30 | $674 |
| Novartis | 35 | $565 |
| Shockwave Medical, Inc | 26 | $562 |
| Abiomed | 10 | $341 |
| Merck | 14 | $232 |
| Pfizer | 12 | $210 |
| Cordis US CORP. | 4 | $193 |
| Amgen | 14 | $187 |
| Philips North America LLC | 8 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $133 |
| Avinger Inc. | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 7 | $100 |
| Astellas Pharma US Inc | 2 | $94 |
| AstraZeneca | 7 | $92 |
| Asahi Intecc USA, Inc. | 5 | $86 |
| Johnson & Johnson | 4 | $66 |
| Novo Nordisk | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Baxter Healthcare | 2 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $33 |
| Gilead | 2 | $25 |
| Cvrx, Inc. | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 2 | $23 |
| Medtronic | 1 | $22 |
| W. L. Gore & Associates, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Elutia, Inc. | 1 | $17 |
| EKOS Corporation | 1 | $17 |
| Terumo Medical Corporation | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUPERA$371
- Mynx Venous VCD$135
- XACT$121
How this compares
$6,628 in reported general payments places this provider in the 45th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 542 | $469,117 |
| XareltoRivaroxaban | 217 | $173,644 |
| EntrestoSacubitril/Valsartan | 152 | $140,682 |
| Repatha SureclickEvolocumab | 107 | $69,851 |
| BrilintaTicagrelor | 37 | $23,281 |
| FarxigaDapagliflozin Propanediol | 15 | $9,408 |
| ClopidogrelClopidogrel Bisulfate | 1,009 | $9,075 |
| Metoprolol Succinate | 418 | $5,287 |
| Isosorbide Dinitrate | 40 | $5,161 |
| Flecainide Acetate | 180 | $4,984 |
| Diltiazem 12hr ErDiltiazem Hcl | 37 | $4,827 |
| Ranolazine ErRanolazine | 48 | $4,632 |
| Losartan Potassium | 496 | $4,348 |
| Carvedilol | 589 | $3,993 |
| Atorvastatin Calcium | 510 | $3,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $210 | $469,117542 claims |
| Johnson & JohnsonXarelto | $66 | $173,644217 claims |
| NovartisEntresto | $565 | $140,682152 claims |
| AstraZenecaBrilinta, Farxiga | $92 | $32,68952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Mountain Home
- Akihiro KobayashiMountain Home$17K
- Timothy BowenMountain Home$8K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
- Stephen BroughtonLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.